A Study of SHR-2173 in Participants With Primary IgA Nephropathy

NCT07354932 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary IgA Nephropathy

Interventions

DRUG: SHR-2173 injection
DRUG: SHR-2173 injection
DRUG: SHR-2173 injection
DRUG: Placebo

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd